Archives for October 2015

Wild Sexx capsules: Don’t buy, don’t use, FDA says

(RNN) – Wild Sexx capsules, don’t buy, don’t use, the FDA says, warning that the sexual-enhancement product contains undeclared ingredients that may lower blood pressure to dangerous levels.

Do not buy, do not use, Ultra SXFuel Up High OctaneAPEXXSuper Dragon 600 or Paradise Suplemento Natural Ultra Plus capsules, the U.S. Food and Drug Administration said in news releases.

Imprimis Pharmaceuticals Hits New 12-Month Low at $5.91 (IMMY)

Imprimis Pharmaceuticals (NASDAQ:IMMY)’s share price reached a new 52-week low during trading on Tuesday , ARN reports. The stock traded as low as $5.91 and last traded at $6.00, with a volume of 42,490 shares trading hands. The stock had previously closed at $6.75.

Warning to 200 patients of chemotherapy drug risk

Approximately 200 cancer patients have been warned they may have been given potentially contaminated chemotherapy drugs.

The Health Service Executive said it was notified this week of a “precautionary” recall of a number of batches of chemotherapy drugs manufactured between September 29 and October 12.

FDA approves use of OxyContin in pediatrics

The FDA has approved OxyContin use for children as young as 11. The department says this is a symbolic move as many doctors have already been prescribing these medications to children.

FDA Warning Letters: Seafood HACCP, Acidified Foods, Drug Residue

A seafood processing company in Texas was warned about ongoing problems meeting federal seafood HACCP regulations in the latest batch of posted warning letters from the U.S. Food and Drug Administration (FDA).

Advaxis offers a tardy defense after FDA puts cancer vaccine on hold

Two weeks after reporting that its cancer vaccine spurred a positive response among a group of cervical cancer patients in a small clinical trial, Advaxis ($ADXS) waited until after the market closed today to reveal that the FDA has placed the same cancer vaccine–axalimogene filolisbac (ADXS-HPV)–on a clinical hold, slamming the brakes on four studies.

FDA approves lung cancer drug

Federal health officials on Friday expanded approval of an innovative Merck drug to treat patients with an advanced form of the most common lung cancer.